SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Abstract Background Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aβ immunotherapy-related vasogenic edema...

Full description

Bibliographic Details
Main Authors: Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Patrick Benoit, Pascal Barneoud, Véronique Taupin, Philippe Bertrand, Philippe Dugay, Béatrice Cameron, Yi Shi, Souad Naimi, Marc Duchesne, Marie Gagnaire, Tim Weeden, Tara Travaline, David Reczek, Leonard Khiroug, Mohamed Slaoui, Pascale Brunel, Hidehiro Fukuyama, Jeffrey Ravetch, Thierry Canton, Caroline Cohen
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Anti-Aβ immunotherapy
Protofibrillar Aβ peptide
Online Access:http://link.springer.com/article/10.1186/s13195-018-0447-y

Internet

http://link.springer.com/article/10.1186/s13195-018-0447-y

Similar Items